Search Results (29,026)

Advanced gastric (GAC) or gastroesophageal junction (GEJAC) adenocarcinoma continues to carry a poor prognosis. Understanding GAC/GEJAC at the molecular level has provided a new understanding and the basis for individualized approaches to treatment. The current biomarker-driven therapy focuses on four areas: microsatellite instability (MSI), human epidermal growth factor receptor-2 (HER2), programmed death ligand-1 (PD-L1) combined positive score, and claudin 18.2 (CLDN18.2). However, because of improving technology, the focus has shifted to cancer cell-surface proteins and peptides. Each of these GAC/GEJAC subgroups provides a different treatment pathway. The agents utilized to treat advanced GAC/GEJAC include immune checkpoint inhibitors (ICIs), chemotherapy, monoclonal antibodies (mAbs), and antibody–drug conjugate (ADC) therapy, as well as bispecific antibodies (BsAbs), but they are certainly not limited to the above. Drug development has shifted in recent years to establish different mechanisms that are attempting more sophisticated and targeted approaches, such as BsAbs and ADCs. Meanwhile, the development of cytotoxics has tapered off. Along with these developments in drug therapy, more therapies directed at CLDN18.2, HER2, MSI, EGFR, HER3 and trophoblast cell-surface antigen 2 (TROP2) are underway. Here we review future areas in advanced GAC, including zanidatamab’s potential role in HER2-positive advanced GAC and deciphering the abundance of anti-CLDN18.2, extending beyond investigative therapies. Full article

The CD33 rs12459419 (C>T; Ala14Val) single-nucleotide polymorphism (SNP) has been reported to modulate treatment response and survival in pediatric patients with acute myeloid leukemia (AML) receiving gemtuzumab ozogamicin (GO), an anti-CD33 antibody linked to the cytotoxic compound calicheamicin. However, it remains unclear whether this SNP also affects CD33 expression on leukemic blasts. Moreover, its prognostic significance in adult AML patients treated with standard chemotherapy without GO has not been investigated. In this study, we retrospectively genotyped 184 adult AML patients who received standard induction chemotherapy for the CD33 rs12459419 SNP genotype and collected CD33 expression data. The observed genotype distribution was 46% (n = 85) CC, 43% (n = 79) CT, and 11% (n = 20) TT. CD33 expression was detected in significantly higher proportions of leukemic blasts in patients with the CC genotype than those with the TT genotype (p = 0.0009). A similar trend was observed between the CT and TT genotypes (p = 0.06). No significant differences in clinical outcome were detected among the three genotype cohorts. Grouping CC and CT genotypes together based on their similar CD33 expression and comparing them to patients with the TT genotype also revealed no differences in overall survival (OS), event-free survival (EFS), or relapse-free survival (RFS). Using a proportion of 90% CD33-positive blasts to define high versus low expression groups also failed to identify a meaningful impact on OS, EFS, or RFS, either across genotypes or independent of genotype. In conclusion, our findings indicate that the CD33 rs12459419 SNP does not affect outcomes or survival in adult AML patients receiving standard chemotherapy in the absence of GO. Furthermore, no association was seen between CD33 expression and clinical outcomes between the three genotypes. To our knowledge, this is the first study to investigate the prognostic impact of the CD33 rs12459419 SNP per se on outcome and survival in adult AML patients treated with chemotherapy without GO. Validation in larger patient cohorts is required to conclusively rule out a prognostic role of the CD33 rs12459419 SNP in AML. Full article

Concurrent alcohol and cannabis use (“crossfading”) is increasingly prevalent, especially among adolescents, yet its toxicological impact on pulmonary innate immunity remains largely unexplored. Alveolar macrophages (AMs) orchestrate inflammatory responses in the lung, and dysregulated macrophage polarization is a hallmark of alcohol-associated lung disease. Although alcohol and cannabinoids individually modulate immune function, the mechanisms by which their co-exposure alters macrophage activation and inflammatory signaling in the lung are largely unknown. AMs are highly sensitive to xenobiotic exposure and play a central role in regulating inflammatory and cytotoxic responses. In this study, we investigated how acute ethanol exposure, synthetic cannabinoid exposure, and their combined exposure affect macrophage viability, polarization, and the release of inflammatory mediators via cannabinoid receptor (CB1R/CB2R)-dependent pathways. Human THP-1-derived macrophages and KG-1 macrophage-like cells were exposed to ethanol, the CB1/CB2 agonist WIN 55,212-2, or both, with selective pharmacological antagonism of CB1R and CB2R. Ethanol exposure activated and polarized macrophages toward a pro-inflammatory M1 phenotype, accompanied by increased secretion of pro-inflammatory cytokines MCP-1, TGF-α, IFN-β, IL-6, and TNF-α. In contrast, WIN 55,212-2 promoted anti-inflammatory M2 polarization and increased IL-10 and IL-4 production. Notably, co-exposure to ethanol and WIN produced an antagonistic immunomodulatory response, characterized by the suppression of ethanol-induced M1 polarization and attenuation of pro-inflammatory cytokine release. Mechanistically, pharmacological CB1R blockade reduced ethanol-induced M1 polarization and cytokine secretion, whereas CB2R blockade exacerbated these effects, underscoring divergent roles for cannabinoid receptors in regulating pulmonary macrophage responses. This study provides novel findings demonstrating the mechanism by which alcohol–cannabinoid co-use reshapes macrophage immune phenotypes and identifies the endocannabinoid system as a potential therapeutic target for alcohol-related inflammatory lung disease. Full article

Background: Modern oncology views immune system dysfunction as a key factor in carcinogenesis. The induction of immunogenic cell death (ICD), a form of regulated cell death capable of activating adaptive immunity, represents a promising therapeutic strategy. Damage-associated molecular patterns (DAMPs) play a central role in this process. This review aims to summarize current knowledge of DAMPs, their release mechanisms during ICD, their classification, and their prognostic and therapeutic significance in antitumor immunity. Methods: We systematically reviewed and synthesized literature published in Pubmed and Google Scholar on ICD and DAMPs, focusing on distinct forms of DAMPs which were categorized based on recognition mechanisms (five classes) and cellular origin (extracellular, mitochondrial, nuclear, and cytosolic). Key molecules, their receptors, downstream signaling pathways, and clinical associations were analyzed. Results: The spatiotemporally coordinated release of the pattern of DAMPs promotes dendritic cell maturation, antigen presentation, activation of cytotoxic T lymphocytes, and elimination of tumor cells. DAMPs can exhibit a dual role: they are able to induce sterile inflammation essential for antitumor immunity, but may also contribute to metastasis and chronic inflammation. Among all DAMPs, high-mobility group box 1 (HMGB1, a nuclear DAMP) and calreticulin (CRT, a cytosolic protein) demonstrate the greatest prognostic value. Other DAMPs (e.g., extracellular matrix components, uric acid) act as signal amplifiers during various forms of cell death. Conclusions: Understanding the spatiotemporal dynamics of DAMP release is critical for activating immune responses against malignant cells. Monitoring DAMPs may improve patient stratification, predict therapeutic responses, and enable personalized immunotherapeutic strategies. Further investigation of ICD mechanisms and DAMP release represents a fundamental basis for developing novel anticancer therapies. Full article

Reactive oxygen species (ROS) are integral components of plant signaling networks that mediate interactions between plants and their environment, thereby regulating diverse physiological and biochemical processes. While controlled ROS production is essential for stress perception and signal transduction, excessive ROS accumulation induces oxidative damage. ROS-mediated lipid peroxidation of polyunsaturated fatty acids leads to the formation of highly electrophilic α,β-unsaturated carbonyl compounds collectively referred to as reactive carbonyl species (RCS). Under severe abiotic stress conditions, excessive RCS accumulation exerts cytotoxic effects and causes widespread cellular dysfunction. In contrast, at subtoxic levels, RCS function as important secondary messengers that modulate stress-responsive signaling pathways, including programmed cell death, stomatal regulation, and adaptive responses to abiotic stresses. This review critically synthesizes current advances in understanding the dual roles of ROS and RCS as both damaging agents and signaling molecules in plants. Particular emphasis is placed on the mechanistic basis of ROS-RCS crosstalk and their interactions in abiotic stress tolerance. Furthermore, this review highlights emerging research gaps and outlines future perspectives aimed at translating redox signaling insights into strategies for improving plant stress resilience under changing environmental conditions. Full article

The present study examined the effect of Enterococcus durans cell-free supernatant (CFS) on interleukin (IL) 8, 10 and 1β gene expressions in the intestinal cell line HT-29 treated with Staphylococcus aureus CFS. HT-29 cells were incubated with E. durans CFS or S. aureus CFS, or S. aureus CFS plus E. durans CFS. All concentrations of E. durans CFS did not show cytotoxicity, while the highest treatment (44.9 μg/mL) with S. aureus CFS induced significant cell death. S. aureus CFS did not modify IL-1β gene expression, while E. durans CFS alone or in combination with S. aureus CFS reduced it. Treatment with S. aureus CFS induced greater expression of the IL-8 gene compared to S. aureus CFS plus E. durans CFS. S. aureus CFS alone or in combination with E. durans CFS increased the expression of the IL-10 gene, while E. durans CFS alone did not modify it. These results suggest a potential protective role of the E. durans secretome in mitigating the inflammatory environment in intestinal cells. This treatment could be useful to protect against possible contact with dangerous soluble microbial products present in food. Full article

Cadmium (Cd) is a pervasive environmental contaminant with potent cytotoxic effects in a wide range of organisms. Although autophagy and apoptosis are recognized as major cellular responses to heavy metal stress, the molecular basis of Cd-induced cell death in insects remains insufficiently understood. In this study, we used fifth-instar day-4 (5L4D) larvae of Bombyx mori and the silkworm-derived Bm-12 cell line to investigate the involvement of three core autophagy-related proteins, Bombyx mori Autophagy-related protein 5(BmATG5), Bombyx mori Autophagy-related protein 6(BmATG6), and Autophagy-related protein 8(BmATG8), in Cd-induced autophagy and apoptosis. Exposure to CdCl₂ markedly induced autophagic and apoptotic responses in both larval midgut tissue and Bm-12 cells, as demonstrated by monodansylcadaverine(MDC) staining, Lyso-Tracker Red staining, DAPI and Hoechst 33258 staining, and DNA fragmentation assays. qPCR and Western blot analyses showed significant upregulation of BmATG5, BmATG6, and BmATG8 following Cd exposure. Notably, the cleaved forms tBmATG5-N (24 kDa) and tBmATG6-C (35 and 37 kDa), as well as the lipidated form BmATG8-PE (12 kDa), accumulated substantially under Cd stress. In parallel, intracellular Ca²⁺ levels and calpain activity were significantly increased, suggesting activation of a calcium-dependent regulatory pathway. Pharmacological inhibition experiments further indicated that autophagy and apoptosis are functionally interconnected during the Cd response. Collectively, these findings demonstrate that BmATG5, BmATG6, and BmATG8, together with their processed forms, play central roles in coordinating autophagy–apoptosis crosstalk during Cd-induced cytotoxicity in Bombyx mori. This study provides new mechanistic insight into heavy metal toxicity in insects and expands our understanding of stress-induced programmed cell death during silkworm metamorphosis. Full article

Hypertension is a severe global public health issue. Food-derived angiotensin-converting enzyme (ACE)-inhibitory peptides have shown great potential as safe and effective alternatives to synthetic antihypertensive drugs. Camel milk is rich in bioactive peptides. This study aimed to screen for ACE-inhibitory peptides from hydrolyzed camel casein, explore their inhibitory mechanisms and endothelial protective effects in vitro, and reveal their potential antihypertensive pathways using network pharmacology. This study screened three peptides with angiotensin-converting enzyme (ACE) inhibitory activity from enzymatically hydrolyzed camel casein components: MVPFLQPK, VPFLQPKVM, and QKWKFL, with IC₅₀ values of 277.1, 396.9, and 486.9 μmol/L, respectively. Enzyme inhibition kinetics analysis indicated that MVPFLQPK exhibited a non-competitive inhibition pattern, VPFLQPKVM exhibited a mixed inhibition pattern, and QKWKFL exhibited a competitive inhibition pattern. Molecular docking revealed that all three peptides formed hydrogen bond interactions with ACE, and QKWKFL and VPFLQPKVM directly bound to the enzyme’s active site to inhibit substrate catalysis. Molecular dynamics simulation further confirmed the high stability of the three peptide–ACE complexes, with binding free energies from −34.24 to −51.19 kcal/mol. The primary contributing forces include hydrogen bonds, van der Waals interactions, electrostatic forces, and nonpolar solvation effects. Network pharmacology analysis suggested that these peptides may exert synergistic antihypertensive effects by regulating multiple blood pressure-related pathways, including the renin–angiotensin system, renin secretion, and calcium signaling pathways, by acting on key targets such as ACE, REN, SRC, and MMP9. Cell experiments demonstrated that all three peptides exhibited no cytotoxicity in the Ang II-induced HUVEC injury model, significantly promoted NO release, inhibited ET-1 secretion, and possessed endothelial protective potential. This study investigated the in vitro ACE-inhibitory mechanism of peptides derived from camel milk and their potential role in blood pressure regulation, providing experimental evidence for subsequent in vivo activity validation and the development of functional camel milk protein products. Full article

Trans,trans-2,4-decadienal (tt-DDE), the primary aldehyde component found in cooking oil fumes, is a prevalent environmental pollutant. However, its potential adverse effects on ocular development remain largely unexplored. This study evaluated its toxicity on ocular development and angiogenesis in zebrafish larvae, as well as on human retinal vascular endothelial cells (HRECs). Zebrafish (Danio rerio) larvae at 48 h post-fertilization were microinjected intraocularly with various doses of tt-DDE (65.87–521.3 mM) for 24 h. We observed dose-dependent impairments in ocular development following tt-DDE exposure. It significantly reduced eye size and inhibited the intraocular vascular area at concentrations of 128.9 mM and above. Histopathological analysis revealed retinal structural disorganization, eye shrinkage, and a clear dose-dependent increase in acridine orange (AO) fluorescence intensity. Apoptosis assays confirmed a significant escalation in ocular cell death at higher exposure doses. Additionally, our results demonstrated that tt-DDE (5–100 μM) significantly reduced the viability of HRECs in vitro. These findings suggest that early-life exposure to tt-DDE impairs ocular development in zebrafish by inducing histopathological damage, inhibiting angiogenesis, and promoting apoptosis, and also exerts direct cytotoxicity to human retinal cells. This study underscores the potential risk of tt-DDE exposure as an environmental factor contributing to ocular developmental toxicity. Full article

Oral diseases remain highly prevalent worldwide and require early diagnosis and continuous monitoring to improve clinical outcomes. Conventional diagnostic methods are often invasive, time-consuming, and limited in their capacity for real-time assessment, which has driven the development of biosensor technologies for point-of-care applications. Among these, cell-based biosensors utilize living cells as sensing elements capable of responding to inflammatory mediators, bacterial toxins, metabolic products, and tumor-associated biomarkers. This narrative review summarizes the principles, cell types, detection mechanisms, and applications of cell-based biosensors in oral health. The literature was identified through a structured search of PubMed, Scopus, Web of Science, and Google Scholar using keywords related to cell-based biosensors, oral diagnostics, salivary biomarkers, periodontal disease, oral cancer, and lab-on-chip technologies. Due to the heterogeneity of biosensor designs and detection methods, the selected studies were analyzed qualitatively. Cell-based biosensors have demonstrated applications in periodontal disease detection, cariogenic biofilm monitoring, oral cancer diagnostics, cytotoxicity testing of dental materials, and salivary biomarker analysis. The integration of microfluidic and lab-on-chip systems enables real-time and multiplex detection, supporting the development of chairside diagnostic platforms in dentistry. However, challenges related to standardization, reproducibility, and clinical validation remain and must be addressed to facilitate broader implementation in routine practice. Full article

Purpose: Inflammatory bowel disease (IBD) is a chronic inflammatory disorder strongly associated with intestinal microbial dysregulation. Although 5-aminosalicylic acid (5-ASA) is widely used in the clinical management of IBD, its therapeutic efficacy is often limited. To address this, the present study aimed to develop a bifidobacterium-derived extracellular vesicle-based drug delivery system (B-MVs@5-ASA) to enhance the therapeutic outcomes of IBD. Methods: B-MVs were isolated by PEG precipitation and loaded with 5-ASA via sonication to obtain B-MVs@5-ASA. Their morphology, particle size, zeta potential, and encapsulation efficiency were analyzed using TEM, DLS, and UV spectrophotometry. Cellular uptake, cytotoxicity (LDH and NO assays), and anti-inflammatory effects were assessed in RAW 264.7 and Caco-2 cells. A DSS-induced colitis mouse model was established to evaluate therapeutic efficacy. Cytokines (ELISA), colon histopathology (H&E), tight-junction proteins (IF), and gut microbiota composition (16S rRNA sequencing) were systematically analyzed. Results: B-MVs@5-ASA exhibited a particle size of 104.3 ± 2.81 nm and an encapsulation efficiency of 11.14% ± 3.63%. B-MVs@5-ASA exhibited the strongest anti-inflammatory effect in vitro and most effectively alleviated DSS-induced colitis in vivo, outperforming monotherapies in reducing inflammation, tissue damage, and enhancing barrier integrity. B-MVs@5-ASA further promoted goblet cell regeneration and beneficially modulated the gut microbiota by enriching Akkermansia and suppressing Escherichia, thereby restoring microbial homeostasis. Conclusions: B-MVs@5-ASA provides potent anti-inflammatory and mucosal-protective effects by modulating cytokine balance, enhancing epithelial barrier function, and reshaping gut microbiota. These findings highlight probiotic vesicle-based nanoplatforms as a safe and promising strategy for targeted IBD therapy. Full article

Difficult-to-treat systemic lupus erythematosus (D2T-SLE) remains a major unmet challenge in contemporary lupus care, yet it continues to be defined predominantly by clinical non-response rather than underlying biology. Current biomarkers largely quantify inflammatory burden, immune complex activity, or organ damage and do not reliably capture persistent activation of pathogenic pathways under therapy. Emerging multi-omics, single-cell, and longitudinal studies suggest that, in a subset of patients, apparent treatment failure may reflect incomplete attenuation of dominant immune circuits rather than uniformly elevated inflammation. We propose molecular refractoriness in systemic lupus erythematosus (SLE) as sustained, pathway-level immune activity despite apparently adequate, mechanism-directed therapy. We outline the major immune programs implicated in this process—including interferon-enriched, B-cell/plasmablast-associated, neutrophil extracellular trap (NET)-related, cytotoxic T-cell, and cytokine-associated states—and discuss their relevance for biomarker development and precision trial design. Importantly, we emphasize that interferon gene signatures (IGS) should be interpreted as context-dependent and non-specific markers of interferon responsiveness, reflecting combined activity of type I, II, and III interferons, and functioning primarily as predictive rather than mechanistic biomarkers. We further highlight critical limitations of a purely endotype-based model, including the need to distinguish true molecular refractoriness from damage-dominant and pseudo-refractory states, as well as the emerging role of immune-reset strategies such as cluster of differentiation 19 (CD19)-directed chimeric antigen receptor T-cell (CAR-T) therapy, which may overcome refractoriness independently of specific pathway dominance. These observations suggest that difficult-to-treat SLE encompasses biologically heterogeneous states that may not be fully captured by pathway-resolved stratification alone. Reframing D2T-SLE as a biologically heterogeneous state of incomplete immune attenuation may help bridge the gap between clinical treatment failure and mechanism-informed precision medicine in systemic lupus erythematosus. Full article

Given its highly aggressive nature and poor clinical outcome, pancreatic ductal adenocarcinoma (PDAC) requires physiologically relevant in vitro models that more accurately reflect tumor biology and drug response. In this study, adhesive and non-adhesive hydrogel microenvironments were comparatively evaluated for pancreatic cancer spheroid modeling using PANC-1 and MIA PaCa-2 cells. Gelatin methacryloyl (GelMA) hydrogels were synthesized, photocrosslinked, and optimized in terms of stability, swelling, degradation, and cytocompatibility, while 3% agarose was used as a non-adhesive counterpart. Although the optimized GelMA formulation showed adequate structural stability and no cytotoxicity, it did not support spheroid formation. In contrast, agarose enabled the formation of compact, viable, and proliferative spheroids in both cell lines. Agarose-derived spheroids exhibited time-dependent growth, positive Ki-67 staining, and increased HIF-1α expression under 3D conditions, indicating the establishment of hypoxia-associated tumor-like microenvironments. Gemcitabine treatment induced a time-dependent reduction in spheroid viability, while viable cell populations persisted throughout exposure, reflecting the heterogeneous therapeutic response typical of 3D tumor models. Overall, these findings provide a comparative, microenvironment-based assessment of pancreatic cancer spheroid modeling, indicating that hydrogel-dependent differences in adhesivity and structural dynamics are important determinants of spheroid assembly, hypoxia-associated molecular adaptation, and chemotherapeutic response. Overall, these findings provide a comparative, microenvironment-based assessment of pancreatic cancer spheroid modeling, indicating that hydrogel-dependent differences in adhesivity and structural dynamics are important determinants of spheroid assembly, hypoxia-associated molecular adaptation, and chemotherapeutic response. Overall, these findings provide a comparative, microenvironment-based assessment of pancreatic cancer spheroid modeling, indicating that hydrogel-dependent differences in adhesivity and structural dynamics are important determinants of spheroid assembly, hypoxia-associated molecular adaptation, and chemotherapeutic response. Full article

Conventional chemotherapies for cervical cancer, such as cisplatin (CDDP)-based treatments, are limited by high systemic toxicity and the development of cellular resistance. To address these drawbacks, this study reports the green synthesis of selenium nanoparticles (SeNPs) using Amphipterygium glaucum leaf extract (AGLE) and the development of a guar gum-based nanocomposite (SeNPs@GG) loaded with these NPs. The synthesized SeNPs showed a stable UV–Vis absorption band at 275 nm, a spherical morphology, and sizes ranging from 11 to 21 nm, as confirmed by TEM. FTIR and XPS analyses demonstrated interactions between Se and functional groups from the plant extract, indicating its dual role as a reducing and stabilizing agent. The guar gum nanocomposites (NCs) exhibited a porous structure with a homogeneous distribution of SeNPs, as evidenced by SEM and EDS. At the same time, XRD confirmed the crystalline nature of the SeNPs. In vitro cytotoxicity assays using HeLa cervical cancer cells revealed significant antiproliferative effects with a biphasic response related to Se’s dual biological role. The IC₅₀ values were 98.3 µg/mL for SeNPs, 93.7 µg/mL for SeNPs@GG1, and 93.5 µg/mL for SeNPs@GG2. Additional analyses confirmed apoptosis, DNA fragmentation, ROS production, mitochondrial dysfunction, and G2/M cell cycle arrest, supporting the potential of these systems as alternative chemotherapeutic strategies. Full article

Background/objectives: Current treatments for advanced hepatocellular carcinoma (HCC) are tyrosine kinase inhibitors (TKI) and immune checkpoint inhibitors (ICI). When HCC is resistant to TKI or ICI, subsequent available treatments are limited. Dendritic cells (DC) can activate antigen-specific cytotoxic T-cells and may be employed as a subsequent treatment when HCC is resistant to TKI or ICI treatments. Methods: Fifty advanced HCC patients with resistance to ICI or TKI treatment were invited to have autologous DC therapy. DCs were propagated from peripheral blood monocytes and pulsed with tumor lysate. All the patients received ≥3 courses of DC intravenously. For the outcome analysis, 17 patients who were resistant to TKI or other traditional treatments were grouped into A, and 33 patients who were resistant to ICI treatment were grouped into B. Results: For group A patients, the median (interquartile) progression-free and overall survivals were 6 (3–16.3) and 19 (8–24) months, respectively. The 1-, 2- and 3-year overall survivals after DC therapy were 58.2%, 21.8%, and 14.6%, respectively. For group B patients, the median (interquartile) progression-free and overall survivals were 5.0 (4–8) and 9 (5–14.5) months, respectively. The 1-, 2- and 3-year overall survivals after DC therapy were 27.6%, 8.6% and 4.3%, respectively. Taking together 50 patients, the objective response rate was 6.0% and disease control rate was 72.0%. Only three patients (6.0%) had grade I-II hepatitis. Conclusions: DC therapy is a safe treatment for advanced HCC patients. DC can serve as a subsequent therapy to extend the patients’ lives when TKI or ICI treatments are ineffective as advanced HCC treatments. Full article